AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8944861 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal health education intervention with three visits per year from a health visitor.
Number of subjects: 688
Study 8944861 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 688
Study 1924661 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 33
Study 1924661 — intervention group
Group type: COMPARATOR
Intervention: Intermenstrual phase
Number of subjects: 33
Study 1924661 — intervention group
Group type: COMPARATOR
Intervention: Luteal phase
Number of subjects: 33
Study 1924661 — intervention group
Group type: COMPARATOR
Intervention: Menstrual phase
Number of subjects: 33
Study 6805495 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sodium cromoglycate
Number of subjects: 30
Study 6805495 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31296081 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 10942
Study 31296081 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 10942
Study 31296081 — intervention group
Group type: EXPERIMENTAL
Intervention: CEC identified MIs
Number of subjects: 10942
Study 31296081 — intervention group
Group type: EXPERIMENTAL
Intervention: SI reported MIs
Number of subjects: 10942
Study 31296081 — intervention group
Group type: EXPERIMENTAL
Intervention: CEC and SI reported MIs
Number of subjects: 10942
Study 31296081 — intervention group
Group type: EXPERIMENTAL
Intervention: CEC but not SI reported MIs
Number of subjects: 10942
Study 31296081 — intervention group
Group type: EXPERIMENTAL
Intervention: SI but not CEC reported MIs
Number of subjects: 10942
Study 27879959 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance Training (BT)
Number of subjects: 40
Study 27879959 — intervention group
Group type: COMPARATOR
Intervention: Resistance Training (RT)
Number of subjects: 40
Study 26372211 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 79
Study 26372211 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 23232754 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% dextrose‐0.9% saline
Number of subjects: 202
Study 23232754 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 202
Study 21158934 — intervention group
Group type: EXPERIMENTAL
Intervention: UV-B exposure of 3.0 SED for 4 sessions
Number of subjects: 55
Study 21158934 — intervention group
Group type: EXPERIMENTAL
Intervention: UV-B exposure of 0.375 SED for 4 sessions
Number of subjects: 55
Study 19843565 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise therapy for 6 weeks, tailored to individual performance, supervised by a physical therapist, with home exercises for 3 months
Number of subjects: 131
Study 19843565 — intervention group
Group type: COMPARATOR
Intervention: Usual care (wait and see approach, rest during pain, refrain from pain provoking activities)
Number of subjects: 131
Study 17561562 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical betamethasone 0.1%
Number of subjects: 51
Study 17561562 — intervention group
Group type: COMPARATOR
Intervention: Petrolatum
Number of subjects: 51
Study 17561562 — intervention group
Group type: COMPARATOR
Intervention: None (Control)
Number of subjects: 51
Study 15382775 — intervention group
Group type: EXPERIMENTAL
Intervention: Ball-retained overdentures
Number of subjects: 36
Study 15382775 — intervention group
Group type: EXPERIMENTAL
Intervention: Bar-retained overdentures
Number of subjects: 36
Study 15382775 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnet-retained overdentures
Number of subjects: 36
Study 12154263 — intervention group
Group type: EXPERIMENTAL
Intervention: Social problem‐solving telephone partnership intervention
Number of subjects: 74
Study 12154263 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 74
Study 12154263 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 74
Study 9661231 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient treatment
Number of subjects: 98
Study 9661231 — intervention group
Group type: COMPARATOR
Intervention: Supportive housing
Number of subjects: 98
Study 7916925 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg OKT3
Number of subjects: 29
Study 7916925 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg OKT3
Number of subjects: 29
Study 7916925 — intervention group
Group type: COMPARATOR
Intervention: 5 mg OKT3 (initial three doses)
Number of subjects: 29
Study 7916925 — intervention group
Group type: COMPARATOR
Intervention: 10 mg OKT3 (initial three doses)
Number of subjects: 29
Study 1369882 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgically treated cases with wire loop (cerclage)
Number of subjects: 39
Study 1369882 — intervention group
Group type: COMPARATOR
Intervention: Conservatively managed patients
Number of subjects: 39
Study 1369882 — intervention group
Group type: COMPARATOR
Intervention: Patients operated after Weber
Number of subjects: 39
Study 6778673 — intervention group
Group type: EXPERIMENTAL
Intervention: Elementary diet (water, electrolytes, carbohydrates, fat short-chain peptides via a jejunal tube)
Number of subjects: 20
Study 6778673 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (water, electrolytes, and carbohydrates by intravenous route)
Number of subjects: 20
Study 31355654 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness induction
Number of subjects: 0
Study 28087807 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital LAMS
Number of subjects: 1632
Study 28087807 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA LAMS
Number of subjects: 1632
Study 28087807 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA National Institutes of Health Stroke Scale
Number of subjects: 1632
Study 28087807 — intervention group
Group type: COMPARATOR
Intervention: Prehospital LAMS vs EPA National Institutes of Health Stroke Scale
Number of subjects: 1632
Study 28087807 — intervention group
Group type: COMPARATOR
Intervention: Prehospital LAMS vs Prehospital Glasgow Coma Scale
Number of subjects: 1632
Study 26474943 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 20 mg
Number of subjects: 336
Study 26474943 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 40 mg
Number of subjects: 336
Study 26474943 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg
Number of subjects: 336
Study 26474943 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 336
Study 26474943 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan treated arms
Number of subjects: 336
Study 26474943 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan treated dose arms
Number of subjects: 336
Study 23803236 — intervention group
Group type: COMPARATOR
Intervention: C‐MVR group (complete preservation of anterior and posterior mitral leaflets and subvalvular apparatus)
Number of subjects: 128
Study 23803236 — intervention group
Group type: EXPERIMENTAL
Intervention: P‐MVR group (anterior leaflet and subvalvular apparatus excised, posterior leaflet and subvalvular apparatus preserved)
Number of subjects: 128
Study 22306586 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a (40 kD) 180 µg/week and ribavirin 800 mg/day
Number of subjects: 287
Study 22306586 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a (40 kD) and ribavirin
Number of subjects: 287
Study 22306586 — intervention group
Group type: EXPERIMENTAL
Intervention: threshold exposures to both drugs
Number of subjects: 287
Study 22306586 — intervention group
Group type: EXPERIMENTAL
Intervention: ribavirin 1000 or 1200 mg/day
Number of subjects: 287
Study 19765449 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan for 1 year
Number of subjects: 50
Study 19765449 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 50
Study 17531532 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergolide (47 patients)
Number of subjects: 200
Study 17531532 — intervention group
Group type: COMPARATOR
Intervention: Placebo (53 patients)
Number of subjects: 200
Study 17531532 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmedicated patients (Group 1)
Number of subjects: 200
Study 17531532 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmedicated patients (Group 2)
Number of subjects: 200
Study 14984856 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 51
Study 14984856 — intervention group
Group type: COMPARATOR
Intervention: Nitroprusside
Number of subjects: 51
Study 11463136 — intervention group
Group type: EXPERIMENTAL
Intervention: Perospirone 8 to 48 mg/day
Number of subjects: 304
Study 11463136 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol 2 to 12 mg/day
Number of subjects: 304
Study 11463136 — intervention group
Group type: COMPARATOR
Intervention: Mosapramine 50 to 300 mg/day
Number of subjects: 304
Study 10095686 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative cleansing regimens (not specified)
Number of subjects: 0
Study 10095686 — intervention group
Group type: COMPARATOR
Intervention: Soap and water
Number of subjects: 0
Study 2596678 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpleural bupivacaine, 20 ml of a 0.5% solution with adrenaline 5 micrograms/ml
Number of subjects: 24
Study 2596678 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular pethidine, 1 mg/kg
Number of subjects: 24
Study 337989 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane in oxygen in a closed circuit
Number of subjects: 90
Study 337989 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane and 66% nitrous oxide in oxygen in a Magill circuit
Number of subjects: 90
Study 337989 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial ventilation with 66% nitrous oxide in oxygen (IPPV group)
Number of subjects: 90
Study 31776849 — intervention group
Group type: EXPERIMENTAL
Intervention: Health coach, text message, and Fitbit intervention
Number of subjects: 59
Study 31776849 — intervention group
Group type: COMPARATOR
Intervention: Fitbit-only control
Number of subjects: 59
Study 31300528 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-only treatment with booster sessions (n = 44)
Number of subjects: 174
Study 31300528 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-only treatment without booster sessions (n = 43)
Number of subjects: 174
Study 31300528 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (ST) (n = 87)
Number of subjects: 174
Study 28821686 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/d)
Number of subjects: 46
Study 28821686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 25761977 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg/day
Number of subjects: 720
Study 25761977 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride ≤6 mg/day
Number of subjects: 720
Study 23647373 — intervention group
Group type: EXPERIMENTAL
Intervention: Tefinostat (CHR‐2845) at doses of 20‐640 mg, administered orally once daily.
Number of subjects: 18
Study 21072688 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar energy sealing system (B)
Number of subjects: 90
Study 21072688 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonic coagulation (UC)
Number of subjects: 90
Study 19026256 — intervention group
Group type: EXPERIMENTAL
Intervention: High-calorie meal (1000 kcal)
Number of subjects: 0
Study 19026256 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-calorie meal (500 kcal)
Number of subjects: 0
Study 19026256 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie meals (250 kcal)
Number of subjects: 0
Study 19026256 — intervention group
Group type: COMPARATOR
Intervention: Fasting condition
Number of subjects: 0
Study 19026256 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat content of the meal
Number of subjects: 0
Study 17106267 — intervention group
Group type: EXPERIMENTAL
Intervention: rDEN2/4Delta30(ME) vaccine at a dose of 1,000 PFU
Number of subjects: 20
Study 17106267 — intervention group
Group type: EXPERIMENTAL
Intervention: rDEN2/4Delta30(ME) vaccine
Number of subjects: 20
Study 17106267 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15019365 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of 4 mg of triamcinolone acetonide
Number of subjects: 15
Study 15019365 — intervention group
Group type: COMPARATOR
Intervention: Control (non-injected eye)
Number of subjects: 15
Study 11745819 — intervention group
Group type: EXPERIMENTAL
Intervention: SIRT + HAC
Number of subjects: 37
Study 11745819 — intervention group
Group type: COMPARATOR
Intervention: HAC only
Number of subjects: 37
Study 9280873 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin in combination with prolonged oral etoposide (100 mg/d for 14 days)
Number of subjects: 79
Study 9280873 — intervention group
Group type: COMPARATOR
Intervention: Prolonged oral etoposide therapy (100 mg/d for 14 or 21 days)
Number of subjects: 79
Study 9280873 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin in combination with prolonged oral etoposide
Number of subjects: 79
Study 8516090 — intervention group
Group type: EXPERIMENTAL
Intervention: Phototherapy alone
Number of subjects: 208
Study 8516090 — intervention group
Group type: EXPERIMENTAL
Intervention: Phototherapy plus oral agar
Number of subjects: 208
Study 8516090 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral agar alone
Number of subjects: 208
Study 8516090 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 208
Study 3102414 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast neutron therapy
Number of subjects: 168
Study 3102414 — intervention group
Group type: COMPARATOR
Intervention: 4MV photon therapy
Number of subjects: 168
Study 29429057 — intervention group
Group type: EXPERIMENTAL
Intervention: Stainless steel K-files (SSK)
Number of subjects: 24
Study 29429057 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Adjusting File (SAF)
Number of subjects: 24
Study 29429057 — intervention group
Group type: EXPERIMENTAL
Intervention: ProTaper NEXT (PTN)
Number of subjects: 24
Study 29429057 — intervention group
Group type: EXPERIMENTAL
Intervention: RECIPROC (REC)
Number of subjects: 24
Study 29429057 — intervention group
Group type: EXPERIMENTAL
Intervention: SAF
Number of subjects: 24
Study 29429057 — intervention group
Group type: EXPERIMENTAL
Intervention: SSK
Number of subjects: 24
Study 29429057 — intervention group
Group type: EXPERIMENTAL
Intervention: PTN
Number of subjects: 24
Study 29429057 — intervention group
Group type: EXPERIMENTAL
Intervention: REC
Number of subjects: 24
Study 26980264 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diltiazem (3 times a day)
Number of subjects: 34
Study 26980264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 24448757 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystone supplement with cisplatin (group B)
Number of subjects: 49
Study 24448757 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin without cystone (group A)
Number of subjects: 49
Study 21900941 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg
Number of subjects: 1316
Study 21900941 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg
Number of subjects: 1316
Study 21900941 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 75 mg
Number of subjects: 1316
Study 21900941 — intervention group
Group type: COMPARATOR
Intervention: Ramipril 5 mg
Number of subjects: 1316
Study 20492052 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation training
Number of subjects: 27
Study 20492052 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 27
Study 18954260 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (RSG)
Number of subjects: 0
Study 18954260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17214048 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual fetal stimulation (MST)
Number of subjects: 540
Study 17214048 — intervention group
Group type: COMPARATOR
Intervention: Nonstress test (NST)
Number of subjects: 540
Study 12488271 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin
Number of subjects: 17
Study 12488271 — intervention group
Group type: COMPARATOR
Intervention: Conventional AEDs
Number of subjects: 17
Study 12488271 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 17
Study 11022177 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal octreotide (for at least 9 to 12 months); n=42
Number of subjects: 442
Study 11022177 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous octreotide (mean exposure of 3 years); n=231
Number of subjects: 442
Study 11022177 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular Sandostatin LAR (mean exposure of 2.5 years); n=47
Number of subjects: 442
Study 11022177 — intervention group
Group type: EXPERIMENTAL
Intervention: All populations (including n=141 for cross-reaction testing)
Number of subjects: 442
Study 8637792 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonnutritive sucking (NNS) during prefeeding
Number of subjects: 13
Study 8637792 — intervention group
Group type: COMPARATOR
Intervention: Control (no NNS)
Number of subjects: 13
Study 1517612 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh gas flow of 81/minute during Phase I
Number of subjects: 15
Study 1517612 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh gas flow of 5.61/minute during Phase II
Number of subjects: 15
Study 1517612 — intervention group
Group type: EXPERIMENTAL
Intervention: Both phases
Number of subjects: 15
Study 6475984 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxalactam plus piperacillin
Number of subjects: 136
Study 6475984 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxalactam plus amikacin
Number of subjects: 136
Study 30122328 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-weeks of interval exercise at 60%-75% Wattpeak
Number of subjects: 66
Study 30122328 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no exercise)
Number of subjects: 66
Study 30004914 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum Block with placebo
Number of subjects: 125
Study 30004914 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Lidocaine
Number of subjects: 125
Study 30004914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 26655924 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 27
Study 26655924 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical sleeve gastrectomy
Number of subjects: 27
Study 26655924 — intervention group
Group type: COMPARATOR
Intervention: Hypocaloric diet (HC diet)
Number of subjects: 27
Study 24625010 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational Pain Management Protocol (Protocol) implemented for 12 weeks after 4 weeks of baseline assessment and staff training.
Number of subjects: 122
Study 24625010 — intervention group
Group type: COMPARATOR
Intervention: Usual pain management strategies in control care homes.
Number of subjects: 122
Study 22183078 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobutrol (0.15 mmol/kg)
Number of subjects: 20
Study 22183078 — intervention group
Group type: COMPARATOR
Intervention: Gadopentetate dimeglumine (0.20 mmol/kg)
Number of subjects: 20
Study 20088738 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated ambient particles (CAP)
Number of subjects: 23
Study 20088738 — intervention group
Group type: EXPERIMENTAL
Intervention: CAP + Ozone (O3)
Number of subjects: 23
Study 20088738 — intervention group
Group type: COMPARATOR
Intervention: Filtered Air (FA)
Number of subjects: 23
Study 18836324 — intervention group
Group type: EXPERIMENTAL
Intervention: Bensal HP (QRB7)
Number of subjects: 40
Study 18836324 — intervention group
Group type: COMPARATOR
Intervention: Silver sulfadiazine cream (SSC)
Number of subjects: 40
Study 16297752 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-cm group (threading the epidural catheter 10 cm then retracting 5 cm)
Number of subjects: 80
Study 16297752 — intervention group
Group type: COMPARATOR
Intervention: 5-cm group (threading the epidural catheter 5 cm)
Number of subjects: 80
Study 16297752 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-cm group
Number of subjects: 80
Study 16297752 — intervention group
Group type: COMPARATOR
Intervention: 5-cm group
Number of subjects: 80
Study 11939922 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2‐pneumoperitoneum (13 mmHg) in supine position
Number of subjects: 30
Study 11939922 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2‐pneumoperitoneum (13 mmHg) in head-up position
Number of subjects: 30
Study 11939922 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2‐pneumoperitoneum (13 mmHg) in head-down position
Number of subjects: 30
Study 11939922 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-down position with pneumoperitoneum
Number of subjects: 30
Study 11939922 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (supine, head-up, head-down)
Number of subjects: 30
Study 10225478 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE-Inhibitors
Number of subjects: 35
Study 10225478 — intervention group
Group type: COMPARATOR
Intervention: beta-blockers
Number of subjects: 35
Study 10225478 — intervention group
Group type: COMPARATOR
Intervention: calcium antagonists
Number of subjects: 35
Study 10225478 — intervention group
Group type: COMPARATOR
Intervention: no pharmacological treatment
Number of subjects: 35
Study 8550304 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA)
Number of subjects: 26
Study 8550304 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular (IM) injections of narcotics
Number of subjects: 26
Study 2142901 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofibate
Number of subjects: 44
Study 2142901 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 44
Study 2142901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 95728 — intervention group
Group type: EXPERIMENTAL
Intervention: Minoxidil in combination with propranolol and diuretics
Number of subjects: 0
Study 95728 — intervention group
Group type: COMPARATOR
Intervention: Other drugs (comparable group)
Number of subjects: 0
Study 30040002 — intervention group
Group type: EXPERIMENTAL
Intervention: Polarized training
Number of subjects: 22